Dr. Jeff Barrett will lead C-Path’s RDCA-DAP initiative focusing on rare disease data sharing and accelerating therapy development.
TUCSON, Ariz. May 6, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jeff Barrett, Ph.D., F.C.P., as Senior Vice President and lead for its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) initiative.
Dr. Barrett comes to the role internally, from his pervious role as Senior Advisor to the organization, while working closely with C-Path’s Quantitative Medicine Program. He was previously head of quantitative sciences at the Bill & Melinda Gates Medical Research Institute (MRI) where he was responsible for implementing model-based drug development, employing PK/PD modeling, statistics and clinical trial simulations to advance the discovery and development of new medicines and vaccines.
“With more than 30 years of diverse experience in quantitative science, we are honored to add Jeff to our executive leadership team and have him step in to lead the RDCA-DAP initiative focused on advancing therapies for rare diseases,” said C-Path Interim President and COO Kristen Swingle, M.S.
Prior to MRI, Jeff was Vice President of Translational Informatics at Sanofi Pharmaceuticals. He led various aspects of model-based decision-making and provided leadership for Sanofi’s cloud-based, high-performance computing and “big data” initiatives.
As SVP, and in partnership with senior leadership, Dr. Barrett will guide all operational and scientific activities for RDCA-DAP. These activities will include continuing outreach and collaboration with the rare disease community to optimize data usability and availability, as well as transforming such data into actionable knowledge to advance drug development for rare and orphan conditions. He will also spearhead the public launch of the platform in September 2021.
“Jeff’s experience and current work embodies C-Path’s vision of being a partner of excellence in transforming the medical product development process worldwide,” said C-Path Chief Science Officer Klaus Romero, M.D., M.S., F.C.P. “We are looking forward to the impact Jeff will have on RDCA-DAP and the rare disease drug development ecosystem.”
RDCA-DAP is a collaboration between C-Path and the National Organization for Rare Disorders (NORD) created to provide a centralized and standardized infrastructure to accelerate and optimize the quantitative characterization of rare diseases, with the goal of accelerating therapy development. Dr. Barrett succeeds Jane Larkindale, D.Phil., Executive Director of RDCA-DAP since its inception in 2019.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 55% funded by FDA/HHS, totaling $14,575,306, and 45% funded by non-government source(s), totaling $11,916,747. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit FDA.gov.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.